Sodium sulfobutylether β-cyclodextrin CAS NO.182410-00-0

Sodium sulfobutylether β-cyclodextrin Product Name: Betadex Sulfobutylether sodium;SBE-β-CD;SBECD CAS No.: 182410-00-0 MWt: 1451.29 Formula: C50H84Na2O41S2 Purity : 98% Solubility: Water:100 mg/ml Mechanisms: Pathways: Others; Target: Others Usage β-Cyclodextrin with sulfobutyl ether groups and sodium ions substituted along the length of the molecule. β-Cyclodextrin is a cyclic oligosaccharide produced from starch via enzymatic conversion. β-C yclodextrin is commonly used to produce HPLC columns allowing chiral enantiomers separation. Usage SBE- β -CD is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Synonyms: beta.-Cyclodextrin, sulfobutyl ethers, sodium salts; Sodium sulfobutylether β-cyclodextrin;Betadex Sulfobutyl Ether Sodium sulfobutyl ether B-cyclodextrin;sodiuM salts; sulfobutyl ethers;SodiuM Sulphobutylether-β-Cyclodextrin Biological Activity: SBE-β-CD (Sulfobutylether-β-Cyclodextrin; Captisol) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs; Captisol is the trademark of SBE-β-CD registered by Ligand Pharmaceuticals. IC50 value: Target: Drug adjuvant SBE-β-CD is a unique reproducible mixture of polyanionic β-cyclodextrin derivatives in which a sodium sulfonate salt is tethered to the lipophilic cyclodextrin cavity by a butyl ether group, or sulfobutylether (SBE). The sulfobutyl ether (SBE) substituent is introduced at the 2, 3, and 6 positions in one or more of the glucopyranose units in the cyclodextrin structure. The introduction of SBE substituents onto the β-cyclodextrin can produce preparations with different overall average degrees of substitution due to the proportion of multiple species present with different degrees of substitution, theoretically from 1 to 21 sites for substitution. SBE-β-CD, with on average 7 such SBE substituents per β-cyclodextrin, introduced by way of a reproducible patent-protected process, was chosen as the cyclodextrin preparation with the most desirable safety profile and drug association properties.